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Activity-based protein profiling (ABPP) is emerging as a game-changing tool for drug discovery, target
validation, and basic biology. In this issue, Chang et al. (2011) report the ABPP-facilitated discovery of
JW480, a highly selective potent and orally bioavailable inhibitor of monoalkylglycerol ether hydrolase
KIAA1363 that dramatically impairs in vivo growth of human prostate cancer cell lines.Identification and characterization of the
functionally diverse enzyme complexes
that coordinate and control all cellular
processes is among the most important
challenges of the postgenomic era. Quan-
titative understanding of dynamic enzyme
activity, integrated from the cell up to
the whole organism, is an essential step
towardaunifiedmodel of life, andapower-
ful tool in the increasingly complex search
for viable drug targets across all diseases.
To understand enzyme function, we must
decipher the emergent chemistry of
proteins, and the application of chemical
technologies to this challenge has proven
particularly powerful, giving rise to the
vibrant multidiscipline of chemical proteo-
mics. An ultimate objective of this
emerging field is to profile all types of
enzymatic activity in whole organisms,
a process commonly termed Activity-
Based Protein (or Proteome) Profiling
(ABPP), presenting some fascinating chal-
lenges in chemical biology (Heal et al.,
2011). ABPP has origins in work from the
1980s, labeling theactive siteofproteases,
but it is only recently that it has matured
into a versatile andpowerful platform tech-
nology. The Cravatt laboratory is a recog-
nizedABPPpioneer, havingdemonstrated
profiling across a remarkably broad range
of enzyme classes. In a notable recent
study, a search for selective inhibitors ofmembers of the serine hydrolase (SH)
superfamily (Bachovchin et al., 2010) was
implemented using competitive ABPP, in
which synthetic molecules compete with
the probe for binding to the target enzyme.
In this case, an SH-directed fluorophosph-
onate-rhodamine (FP-Rh) probe was used
to profile over 70 hydrolases against more
than 150 carbamate inhibitors, ultimately
resulting in compounds selective toward
single or small groups of SHs. Competitive
ABPP is a perfect fit to the aspirations of
modern drug discovery, allowing fine
tuning of inhibitor selectivity and potency
against numerous enzymes in parallel,
directly in the native complexity of the
proteome. Furthermore, even inhibitors
that are selective for or against uncharac-
terized enzymes for which substrates
have not yet been reported can be devel-
oped utilizing this methodology. The impli-
cations for understanding inhibitor on- and
off-targets in vivo during drug develop-
ment are evident, and ABPP holds great
promise for avoiding drug attrition due to
toxicity or efficacy failures in late-stage
clinical trials.
In the current issue, Ben Cravatt and
coworkers (Chang et al., 2011) report the
development of JW480, a potent and
selective carbamate-based inhibitor of
KIAA1363 (also known as AADACL1),
which is a membrane-bound 2-acetylmonoalkylglycerol ether hydrolase. KIAA
1363 is a member of the aforementioned
abundant and diverse SH superfamily,
which includes esterases, thioesterases,
lipases, amidases, and proteases. Sev-
eral SHs are implicated in the develop-
ment and progression of tumors (Nomura
et al., 2010a), but unfortunately the bio-
logical and physiological functions for
many of these potential pharmacological
targets remain poorly understood (Simon
and Cravatt, 2010). Increased activity of
KIAA1363 results in the overproduction
of monoalkylglycerol ethers (MAGEs),
which in turn are converted into lyso-
phospholipids that stimulate survival,
mobility, and aggressiveness of cancer
cells (Chiang et al., 2006). KIAA1363 is
the second SH enzyme reported recently
by the same group to lead to overproduc-
tion of protumorigenic lipids. In the former
study, a combination of ABPP, proteomic,
and lipidomic analyses revealed a key role
for monoacylglycerol lipase (MAGL) in
leveling these fats (Nomura et al., 2010b).
The current study evolves from this
work, focusing on the KIAA1363-MAGE
pathway in prostate cancer cells with
recently discovered lead compounds
(Bachovchinetal., 2010), providingastart-
ing point for rational design ofmore potent
and selective analogs. In initial experi-
ments, increased activity of KIAA1363,ª2011 Elsevier Ltd All rights reserved 407
Figure 1. Discovery of JW480: Activity-Based Protein Profiling in Action
ABPP-assisted discovery of selective inhibitor JW480 against serine protease KIAA1363, the activity of which is upregulated in aggressive cancer cells. Orally
administered JW480 also significantly impaired the growth of tumor in a mouse xenograph model.
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PAGE-fluorescence readout (Figure 1),
was shown to correlate with elevated
levels of MAGE in aggressive cancer cell
lines. Next, a sizable library of carbamates
was designed and tested, ultimately re-
sulting in JW480, a highly selective and
potent (IC50 = 6 nM) mechanism-based
inhibitor of KIAA1363 in living aggressive
prostate cancer cells. The authors lever-
aged competitive and quantitative vari-
ants of ABPP technology to demonstrate
that the inhibitory action of JW480 (1 mM)
is maintained in these cells for at least
48 hr with no signs of off-target reactivity,
with the exception of carboxylesterase
ES1, a cross-reactivity target common
for carbamates. Furthermore, highly se-
lective inhibition of mouse brain KIAA
1363 by JW480 can be achieved in vivo,
which has striking potential implications
in the context of brain tumor progression
(Albert and Anderson, 1977) and lipid
signaling in the CNS. Finally, in an aggres-
sive prostate cancer model (Figure 1),
severe reduction, but not complete408 Chemistry & Biology 18, April 22, 2011 ªblockage, of tumor growth was observed
in mice to which JW480 was administered
orally.
The data presented make a strong case
for JW480 as a near-ideal tool for further
studies on the cellular biochemistry of
hydrolaseKIAA1363 and the lipid signaling
network within which it is embedded.
The authors have delivered a useful and
practical compound that is readily synthe-
sized, orally bioavailable, and CNS pene-
trant, with important potential applications
extending beyond cancer to CNS and
metabolic disorders (Homan et al., 2011).
Most importantly to scientists trying to
understand lipid signaling, by exploiting
the power of ABPP, the authors have
gone much further than traditional
biochemical approachespermit to validate
the on-target effect of their compounds
and eliminate potential off-target effects.
In future investigations, itwill be interesting
to see whether bio-orthogonally tagged or
fluorescent analogs of JW480 can be used
to cross-confirm selectivity in a manner
not biased toward the SH superfamily2011 Elsevier Ltd All rights reservedand for in vivo imaging studies of
KIAA1363 activity. The other standout
featureof thiswork is theelegantcombina-
tion of activity-based proteomics with
targeted lipidomics, resulting in new infor-
mation about the role of the target enzyme
in the network as a whole. Taking this
a step further, potential feedback of aber-
rant lipidmetabolism into changes in post-
translational lipidation of proteins is an
intriguing prospect for future exploration,
since aberrant protein lipidation is also
implicated in the progression of cancer
(Heal and Tate, 2010). As ABPP becomes
integrated with other high-throughput
postgenomic and postproteomic tools,
a multidimensional analytical platform is
now on the horizon that has the potential
to revolutionize both modern drug
discovery and our fundamental under-
standing of living systems.REFERENCES
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Studies using chemical inhibitors have suggested that p38 MAP kinase is a key regulator of Wnt/b-catenin
signaling. In this issue, Verkaar et al. (2011) show that cross-reactivity of p38 inhibitors with casein kinase
Id/3 is responsible for Wnt/b-catenin pathway inhibition.Wnt proteins are members of an evolu-
tionarily conserved family of signaling
molecules that play a central role in
embryonic development and adult tissue
homeostasis (Logan and Nusse, 2004).
Given this wide array of functions, it is
not surprising that the deregulation of
Wnt signaling is associated with a range
of human diseases (Clevers, 2006); chief
among these is cancer, providing a major
incentive to define the molecular mecha-
nism ofWnt signaling and to find inhibitors
that can be used to target the Wnt
pathway in cancer treatment.
In recent years, a detailed outline of the
Wnt signaling mechanism has emerged.
Wnt can signal through several distinct
pathways, but the major pathway related
to stem cell maintenance and cancer is
the so-called canonical Wnt/b-catenin
pathway (MacDonald et al., 2009). A
central player in this pathway is b-catenin,
which interacts with TCF transcription
factors to co-activate the expression of
Wnt target genes. In the absence of
theWnt ligand, b-catenin levels are down-
regulated by a destruction complex that
consists of the scaffold protein Axin, the
APC tumor suppressor protein, and the
kinases casein kinase Ia (CKIa) and
GSK3b, which phosphorylate b-catenin
to target it for proteasome-mediateddegradation. Binding of Wnt to its re-
ceptors Frizzled and LRP5/6 inhibits
destruction complex function, leading to
stabilization and translocationofb-catenin
to the nucleus. Although themechanismof
destruction complex inhibition is still
poorly understood, it is clear that phos-
phorylation of Disheveled (Dvl) by casein
kinase Id/3 (CKId/3) is an important step in
this process (Bryja et al., 2007; Gao et al.,
2002). Recently, the MAP kinase p38
has been implicated in Wnt/b-catenin
signaling as well (Bikkavilli et al., 2008).
To identify low molecular weight
compounds that inhibit the Wnt/b-catenin
pathway, Verkaar et al. (2011) developed
an elegant b-galactosidase complemen-
tation assay to detect translocation of
b-catenin into the nucleus. In the study
published in this issue of Chemistry &
Biology, they applied this method to
screena relatively small collectionofa little
over 2000 compounds and found that two
compounds, TAK-715 and AMG-548,
potently inhibit theWnt-dependent stabili-
zation of b-catenin (Verkaar et al., 2011).
TAK-715 and AMG-548 were previously
characterized as inhibitors of p38 MAP
kinase, which would be in agreement
with the reported role of p38 in the
Wnt/b-catenin pathway (Bikkavilli et al.,
2008). However, further characterizationof TAK-715 and AMG-548 using a panel
of kinases revealed that these com-
pounds also inhibit CKId/3. This finding
prompted the question of whether the
two compoundsmight inhibit Wnt/b-cate-
nin signaling through CKId/3 instead of
p38. Consistent with this notion, it was
found that selective p38 inhibitors that
do not cross-react with CKId/3 have no
effect on Wnt/b-catenin signaling, raising
doubts about the role of p38 in this
signaling pathway. Indeed, Verkaar et al.
(2011) found that knockdown of p38 did
not interfere with the Wnt-dependent
phosphorylation of Dvl, and that p38 was
not activated after Wnt stimulation.
This study has several important impli-
cations. First, it shows that results ob-
tained with kinase inhibitors should be
interpreted with caution and that potential
cross-reactivity with other kinases should
be rigorously tested. Second, the study
provides compelling evidence that p38
MAP kinase is not involved in Wnt/b-
catenin signaling. Finally, TAK-715 and
AMG-548 are clinically evaluated com-
pounds that can now be repositioned for
the treatment of Wnt-dependent tumors.
As TAK-715 and AMG-548 target the
Wnt pathway at the level of CKId/3, it is
unlikely that they will be effective in tumors
harboring mutations in downstreamª2011 Elsevier Ltd All rights reserved 409
